Details werden geladen...
Merck-Kelun lung cancer drug cut risk of tumor progression by 65%, ASCO abstract shows
A type of targeted chemotherapy developed by China-based Kelun-Biotech and licensed to Merck cut the risk of tumor progression by 65% in patients with
Ähnliche Seiten
Merck (MRK) Stock Surges on Breakthrough Lung Cancer Combination Therapy Results - Blockonomi
https://blockonomi.com/merck-mrk-stock-surges-on-breakthrough-lung-cancer-combination-therapy-results/
Kelun-Biotech to Present Two Registrational Studies in the Oral Presentation Session on Non-Small Cell Lung Cancer at ASCO 2026 | The Manila Times
https://www.manilatimes.net/2026/05/22/tmt-newswire/pr-newswire/kelun-biotech-to-present-two-registrational-studies-in-the-oral-presentation-session-on-non-small-cell-lung-cancer-at-asco-2026/2349758
OPUS 4 | Abstract 6532: Higher Lachnoanaerobaculum abundance in the oral microbiome go along with higher levels of tumor-infiltrating lymphocytes and improved survival in head-and-neck cancer patients...
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/130344
Prolocor Inc: Prolocor Announces Results of NIH-funded Study Demonstrating That Platelet Fc?RIIa Identifies Cancer Patients at Increased Risk of Death and Thrombotic Events
https://www.finanznachrichten.de/nachrichten-2026-05/68549919-prolocor-inc-prolocor-announces-results-of-nih-funded-study-demonstrating-that-platelet-fc-riia-identifies-cancer-patients-at-increased-risk-of-death-200.htm
California’s Intuit to slash thousands of jobs, cut workforce by 17%, internal memo shows
https://nypost.com/2026/05/20/business/intuit-to-lay-off-thousands-of-employees-slash-workforce-by-17/